Moody National Bank Trust Division’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $414K | Sell |
46,163
-11,989
| -21% | -$107K | 0.04% | 362 |
|
|
2025
Q1 | $436K | Sell |
58,152
-2,218
| -4% | -$16.6K | 0.05% | 358 |
|
|
2024
Q4 | $454K | Hold |
60,370
| – | – | 0.05% | 356 |
|
|
2024
Q3 | $459K | Buy |
60,370
+8,324
| +16% | +$63.3K | 0.05% | 356 |
|
|
2024
Q2 | $322K | Hold |
52,046
| – | – | 0.03% | 373 |
|
|
2024
Q1 | $264K | Hold |
52,046
| – | – | 0.02% | 407 |
|
|
2023
Q4 | $312K | Hold |
52,046
| – | – | 0.02% | 401 |
|
|
2023
Q3 | $368K | Buy |
52,046
+9,565
| +23% | +$67.7K | 0.02% | 458 |
|
|
2023
Q2 | $299K | Buy |
42,481
+4,893
| +13% | +$34.4K | 0.02% | 512 |
|
|
2023
Q1 | $313K | Buy |
37,588
+11,867
| +46% | +$99K | 0.03% | 498 |
|
|
2022
Q4 | $295K | Buy |
25,721
+310
| +1% | +$3.56K | 0.03% | 491 |
|
|
2022
Q3 | $320K | Buy |
+25,411
| New | +$320K | 0.03% | 442 |
|
|
2019
Q2 | – | Sell |
-667
| Closed | -$5K | – | 430 |
|
|
2019
Q1 | $5K | Buy |
+667
| New | +$5K | ﹤0.01% | 862 |
|